CD19 and acute lymphoblastic leukemia: Among patients with CD19-positive ALL who relapsed after murine scFv CD19 CAR-T treatment, the humanized CD19 CAR-T CR rate (50%-64%) was still lower than in patients who had not received CAR-T therapy (37, 38).